Pfizer Presents Evidence of IBRANCE Effectiveness in HR+, HER2- Metastatic Breast Cancer Patients in Four Real-World Studies
September 24, 2019
September 24, 2019
NEW YORK, Sept. 24 -- Pfizer, a pharmaceutical company, issued the following news release:
Pfizer Inc. (NYSE: PFE) today announced the presentation of four IBRANCE(R) (palbociclib) real-world analyses. The studies support the effectiveness of IBRANCE combination therapy in everyday clinical practice and provide additional insights on its use in certain patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (M . . .
Pfizer Inc. (NYSE: PFE) today announced the presentation of four IBRANCE(R) (palbociclib) real-world analyses. The studies support the effectiveness of IBRANCE combination therapy in everyday clinical practice and provide additional insights on its use in certain patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (M . . .